CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive (Loss) Income
Beginning balance (in shares) at Dec. 31, 2023		70,116,357
Beginning balance at Dec. 31, 2023	$ 78,957	$ 0	$ 341,514	$ (262,667)	$ 110
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common shares from stock option exercises (in shares)		92,893
Issuance of common shares from stock option exercises	357		357
Issuance of common shares from the employee stock purchase plan (in shares)		113,959
Issuance of common shares from the employee stock purchase plan	1,020		1,020
Vesting of restricted stock units (in shares)		2,220,075
Common stock withheld related to net settlement of equity awards (in shares)		(861,017)
Common stock withheld related to net settlement of equity awards	(9,422)		(9,422)
Stock-based compensation	15,063		15,063
Foreign currency translation adjustments, net of tax	(309)				(309)
Net unrealized gain (loss) on investments	(87)				(87)
Net loss	(15,756)			(15,756)
Ending balance (in shares) at Jun. 30, 2024		71,682,267
Ending balance at Jun. 30, 2024	69,823	$ 0	348,532	(278,423)	(286)
Beginning balance (in shares) at Mar. 31, 2024		70,980,371
Beginning balance at Mar. 31, 2024	73,436	$ 0	343,496	(269,870)	(190)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common shares from stock option exercises (in shares)		32,345
Issuance of common shares from stock option exercises	66		66
Vesting of restricted stock units (in shares)		1,014,237
Common stock withheld related to net settlement of equity awards (in shares)		(344,686)
Common stock withheld related to net settlement of equity awards	(3,321)		(3,321)
Stock-based compensation	8,291		8,291
Foreign currency translation adjustments, net of tax	(71)				(71)
Net unrealized gain (loss) on investments	(25)				(25)
Net loss	(8,553)			(8,553)
Ending balance (in shares) at Jun. 30, 2024		71,682,267
Ending balance at Jun. 30, 2024	$ 69,823	$ 0	348,532	(278,423)	(286)
Beginning balance (in shares) at Dec. 31, 2024	73,225,253	73,225,253
Beginning balance at Dec. 31, 2024	$ 66,968	$ 0	358,549	(291,013)	(568)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common shares from stock option exercises (in shares)	86,212
Ending balance (in shares) at Mar. 31, 2025		74,914,866
Ending balance at Mar. 31, 2025	$ 68,581	$ 0	368,919	(299,838)	(500)
Beginning balance (in shares) at Dec. 31, 2024	73,225,253	73,225,253
Beginning balance at Dec. 31, 2024	$ 66,968	$ 0	358,549	(291,013)	(568)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common shares from stock option exercises (in shares)		119,454
Issuance of common shares from stock option exercises	515		515
Issuance of common shares from the employee stock purchase plan (in shares)		118,565
Issuance of common shares from the employee stock purchase plan	1,111		1,111
Issuance of common shares upon the acquisition of Vidurama, Inc. (in shares)		928,691
Issuance of common shares upon the acquisition of Vidurama, Inc.	10,041		10,041
Issuance costs	(26)		(26)
Vesting of restricted stock units (in shares)		2,505,491
Common stock withheld related to net settlement of equity awards (in shares)		(3,497)
Common stock withheld related to net settlement of equity awards	(43)		(43)
Stock-based compensation	17,494		17,494
Foreign currency translation adjustments, net of tax	348				348
Net unrealized gain (loss) on investments	5				5
Net loss	$ (17,536)			(17,536)
Ending balance (in shares) at Jun. 30, 2025	76,893,957	76,893,957
Ending balance at Jun. 30, 2025	$ 78,877	$ 0	387,641	(308,549)	(215)
Beginning balance (in shares) at Mar. 31, 2025		74,914,866
Beginning balance at Mar. 31, 2025	$ 68,581	$ 0	368,919	(299,838)	(500)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common shares from stock option exercises (in shares)	33,242	33,242
Issuance of common shares from stock option exercises	$ 52		52
Issuance of common shares upon the acquisition of Vidurama, Inc. (in shares)		928,691
Issuance of common shares upon the acquisition of Vidurama, Inc.	10,041		10,041
Issuance costs	(26)		(26)
Vesting of restricted stock units (in shares)		1,018,884
Common stock withheld related to net settlement of equity awards (in shares)		(1,726)
Common stock withheld related to net settlement of equity awards	(17)		(17)
Stock-based compensation	8,672		8,672
Foreign currency translation adjustments, net of tax	294				294
Net unrealized gain (loss) on investments	(9)				(9)
Net loss	$ (8,711)			(8,711)
Ending balance (in shares) at Jun. 30, 2025	76,893,957	76,893,957
Ending balance at Jun. 30, 2025	$ 78,877	$ 0	$ 387,641	$ (308,549)	$ (215)